1436 related articles for article (PubMed ID: 20616679)
41. Intravitreal ranibizumab for macular edema secondary to central retinal vein occlusion.
Risard SM; Pieramici DJ; Rabena MD; Basefsky JC; Avery RL; Castellarin AA; Nasir MA; See RF; Couvillion SS
Retina; 2011 Jun; 31(6):1060-7. PubMed ID: 21283055
[TBL] [Abstract][Full Text] [Related]
42. intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic macular edema: a pilot study from the Pan-American Collaborative Retina Study Group.
Wu L; Hernandez-Bogantes E; Roca JA; Arevalo JF; Barraza K; Lasave AF
Retina; 2011 Feb; 31(2):298-303. PubMed ID: 21099452
[TBL] [Abstract][Full Text] [Related]
43. Efficacy of intravitreal triamcinolone for the treatment of macular edema secondary to branch retinal vein occlusion in eyes with or without grid laser photocoagulation.
Cakir M; Dogan M; Bayraktar Z; Bayraktar S; Acar N; Altan T; Kapran Z; Yilmaz OF
Retina; 2008 Mar; 28(3):465-72. PubMed ID: 18327140
[TBL] [Abstract][Full Text] [Related]
44. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema.
Soheilian M; Ramezani A; Obudi A; Bijanzadeh B; Salehipour M; Yaseri M; Ahmadieh H; Dehghan MH; Azarmina M; Moradian S; Peyman GA
Ophthalmology; 2009 Jun; 116(6):1142-50. PubMed ID: 19376585
[TBL] [Abstract][Full Text] [Related]
45. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion.
Rabena MD; Pieramici DJ; Castellarin AA; Nasir MA; Avery RL
Retina; 2007; 27(4):419-25. PubMed ID: 17420692
[TBL] [Abstract][Full Text] [Related]
46. EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION.
Lotfy A; Solaiman KAM; Abdelrahman A; Samir A
Retina; 2018 Sep; 38(9):1795-1800. PubMed ID: 28767552
[TBL] [Abstract][Full Text] [Related]
47. Reading speed improvements in retinal vein occlusion after ranibizumab treatment.
Suñer IJ; Bressler NM; Varma R; Lee P; Dolan CM; Ward J; Colman S; Rubio RG
JAMA Ophthalmol; 2013 Jul; 131(7):851-6. PubMed ID: 23699977
[TBL] [Abstract][Full Text] [Related]
48. Long-term safety and efficacy of intravitreal bevacizumab (Avastin) for the management of central retinal vein occlusion.
Gregori NZ; Gaitan J; Rosenfeld PJ; Puliafito CA; Feuer W; Flynn HW; Berrocal AM; Al-Attar L; Dubovy S; Smiddy WE; Schwartz SG; Lee WH; Murray TG
Retina; 2008 Oct; 28(9):1325-37. PubMed ID: 19430392
[TBL] [Abstract][Full Text] [Related]
49. Comparison of bevacizumab and triamcinolone for treatment of macular edema secondary to central retinal vein occlusion--a matched-pairs analysis.
Guthoff R; Meigen T; Hennemann K; Schrader W
Ophthalmologica; 2010; 224(2):126-32. PubMed ID: 19738392
[TBL] [Abstract][Full Text] [Related]
50. Intravitreal bevacizumab plus grid laser photocoagulation or intravitreal bevacizumab or grid laser photocoagulation for diffuse diabetic macular edema: results of the Pan-american Collaborative Retina Study Group at 24 months.
Arevalo JF; Lasave AF; Wu L; Diaz-Llopis M; Gallego-Pinazo R; Alezzandrini AA; Berrocal MH;
Retina; 2013 Feb; 33(2):403-13. PubMed ID: 23222389
[TBL] [Abstract][Full Text] [Related]
51. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion.
Spaide RF; Chang LK; Klancnik JM; Yannuzzi LA; Sorenson J; Slakter JS; Freund KB; Klein R
Am J Ophthalmol; 2009 Feb; 147(2):298-306. PubMed ID: 18929354
[TBL] [Abstract][Full Text] [Related]
52. Short-term safety and efficacy of intravitreal bevacizumab for pseudophakic cystoid macular edema.
Barone A; Russo V; Prascina F; Delle Noci N
Retina; 2009 Jan; 29(1):33-7. PubMed ID: 18854783
[TBL] [Abstract][Full Text] [Related]
53. Early bevacizumab treatment of central retinal vein occlusion.
Ferrara DC; Koizumi H; Spaide RF
Am J Ophthalmol; 2007 Dec; 144(6):864-71. PubMed ID: 17916320
[TBL] [Abstract][Full Text] [Related]
54. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study.
Kriechbaum K; Michels S; Prager F; Georgopoulos M; Funk M; Geitzenauer W; Schmidt-Erfurth U
Br J Ophthalmol; 2008 Apr; 92(4):518-22. PubMed ID: 18211942
[TBL] [Abstract][Full Text] [Related]
55. Early intravitreal bevacizumab for non-ischaemic branch retinal vein occlusion.
Rensch F; Jonas JB; Spandau UH
Ophthalmologica; 2009; 223(2):124-7. PubMed ID: 19088494
[TBL] [Abstract][Full Text] [Related]
56. [Bevacizumab and Ranibizumab for macular edema due to retinal vein occlusions].
Niederhauser N; Valmaggia C
Klin Monbl Augenheilkd; 2013 Apr; 230(4):405-8. PubMed ID: 23629792
[TBL] [Abstract][Full Text] [Related]
57. Intravitreal bevacizumab for treatment of macular edema secondary to central retinal vein occlusion: eighteen-month results of a prospective trial.
Zhang H; Liu ZL; Sun P; Gu F
J Ocul Pharmacol Ther; 2011 Dec; 27(6):615-21. PubMed ID: 21823986
[TBL] [Abstract][Full Text] [Related]
58. Comparison of intravitreal bevacizumab alone or combined with triamcinolone versus triamcinolone in diabetic macular edema: a randomized clinical trial.
Lim JW; Lee HK; Shin MC
Ophthalmologica; 2012; 227(2):100-6. PubMed ID: 21997197
[TBL] [Abstract][Full Text] [Related]
59. Rebound of macular edema after intravitreal bevacizumab therapy in eyes with macular edema secondary to branch retinal vein occlusion.
Yasuda S; Kondo M; Kachi S; Ito Y; Terui T; Ueno S; Terasaki H
Retina; 2011 Jun; 31(6):1075-82. PubMed ID: 21478810
[TBL] [Abstract][Full Text] [Related]
60. Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: six-month results of a randomized controlled trial.
Lam DS; Lai TY; Lee VY; Chan CK; Liu DT; Mohamed S; Li CL
Retina; 2009 Mar; 29(3):292-9. PubMed ID: 19287286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
